Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy

BACKGROUND AND PURPOSE: CD19-targeting chimeric antigen receptor T-cell (CART) therapy is a promising treatment for relapsed/refractory non-Hodgkin lymphoma, but most patients experience post-CART progression. We describe our institutional experience of salvage radiotherapy (SRT) in this setting. MA...

Descripción completa

Detalles Bibliográficos
Autores principales: Yegya-Raman, Nikhil, Wright, Christopher M., LaRiviere, Michael J., Baron, Jonathan A., Lee, Daniel Y., Landsburg, Daniel J., Svoboda, Jakub, Nasta, Sunita D., Gerson, James N., Barta, Stefan K., Chong, Elise A., Schuster, Stephen J., Maity, Amit, Facciabene, Andrea, Paydar, Ima, Plastaras, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883177/
https://www.ncbi.nlm.nih.gov/pubmed/36718252
http://dx.doi.org/10.1016/j.ctro.2023.100587

Ejemplares similares

Ejemplares similares